Evolent Health Inc (EVH)

Computer Software and Services • Information Technology

Stock AI

News & Reports

July 08, 2026 Evolent Health Inc. Announces Upcoming Second Quarter 2026 Financial Results Evolent Health, Inc. will release its Q2 2026 financial results on August 6, 2026, followed by a conference call at 8 a.m. ET. The call will provide key insights into the company's performance for stakeholders and will also be available for playback for 90 days.

May 07, 2026 Evolent Health Reports Strong Start to 2026 with Q1 Financial Results Evolent Health's Q1 2026 results show a revenue increase to $496 million and a reduced net loss of $26.6 million. The company is expanding its offerings and remains optimistic about future growth despite ongoing medical cost pressures.

April 07, 2026 Evolent Health Inc. Set to Release First Quarter 2026 Financial Results Evolent Health, Inc. is set to release its Q1 2026 financial results on May 7, before market opening. A subsequent conference call will provide insights into the company's performance and strategic initiatives.

March 19, 2026 Evolent Health Inc. Appoints Archie Mayani as Chief Product Officer Evolent Health has announced the appointment of Archie Mayani as Chief Product Officer, aiming to enhance its product strategy with AI innovations. With over 20 years in health care technology, her leadership is expected to drive better health outcomes and streamline processes in the industry.

February 26, 2026 Evolent Health Inc. Announces Participation in Notable Investor Conferences Evolent Health Inc. will participate in two significant investor conferences in March 2026, enhancing its engagement with investors. The company aims to share insights into its innovative healthcare solutions and strategies. Webcasts of the presentations will be available for stakeholders.

February 25, 2026 Evolent Health Inc. Reports Significant Challenges in 2025 Annual Report Evolent Health Inc. struggled in 2025, reporting a 26.6% revenue decline driven by major client changes and regulatory challenges. The company faced substantial operating losses and strategic restructuring efforts, including the sale of Evolent Care Partners.

February 24, 2026 Evolent Health Inc. Reports Fourth Quarter and Full Year 2025 Financial Results Evolent Health, Inc. reported fourth-quarter revenues of $468.7 million and full-year revenues of $1.88 billion for 2025, despite incurring significant losses. The company anticipates a revenue growth of 30% in 2026, driven by its Performance Suite and specialty care solutions amidst ongoing market challenges.

February 04, 2026 Evolent Health Inc. Set to Announce Q4 and Year-End Results Evolent Health Inc. is set to announce its Q4 and year-end 2025 financial results on February 24, 2026. Following the release, a conference call will provide insights from company leadership, with playback available for those unable to attend.

January 02, 2026 Evolent Health Inc. Announces Strategic Inducement Award for New CFO Evolent Health, Inc. has appointed Mario Ramos as its new CFO, awarding him a $2.35 million inducement package to incentivize his leadership. This strategic move highlights Evolent's commitment to attracting top talent and enhancing operational efficiency in delivering healthcare solutions.

November 07, 2025 Evolent Health Inc. Reports Challenging Q3 2025 Financial Results Evolent Health Inc. reported a 22.8% revenue decline in Q3 2025, attributed to rising medical claims and strategic shifts. Despite reducing costs, the company faced a substantial net loss, prompting a need for operational restructuring and strategic adjustments to navigate ongoing industry challenges.

November 06, 2025 Evolent Health and American Oncology Network Launch Innovative Cancer Care Model Evolent Health and the American Oncology Network have partnered to transform cancer care by enhancing quality, affordability, and eliminating prior authorizations. Their innovative model focuses on data-driven insights and patient navigation to improve outcomes for cancer patients.

November 06, 2025 Evolent Health Inc. Reports Strong Q3 2025 Results Amid Industry Growth Evolent Health, Inc. reported solid Q3 2025 results with a revenue of $479.5 million and improved net loss margin. The company is set for growth with new customer agreements and strategic leadership appointments.

October 09, 2025 Evolent Health Inc. Set to Release Q3 2025 Financial Results Evolent Health Inc. will release its Q3 2025 financial results on November 6, 2025, followed by a conference call at 5 p.m. ET. Investors can access the call and learn about upcoming events through the company's investor relations website.

September 23, 2025 Evolent Health Inc. Announces Strategic Sale of Value-Based Primary Care Business Evolent Health has sold its value-based primary care segment to Privia Health for up to $113 million. This strategic move aims to enhance Evolent's focus on specialty care and improve cash flow, with anticipated savings of around $10 million in interest expenses.

August 19, 2025 Evolent Health Inc. Announces Successful Pricing of Convertible Senior Notes Evolent Health has successfully priced $145 million in convertible senior notes due 2031 to improve financial flexibility and repurchase existing debt. This strategic move aims to enhance shareholder value while managing the company’s capital structure effectively.

August 18, 2025 Evolent Health Inc. Announces $140 Million Offering of Convertible Senior Notes Evolent Health Inc. has announced a $140 million offering of convertible senior notes due in 2031, aimed at strengthening its capital structure. The proceeds will be used primarily for repurchasing existing notes and shares, potentially impacting shareholder value and market dynamics.

August 11, 2025 Evolent Health Inc. Reports Q2 2025 Financial Results: Navigating a Challenging Landscape Evolent Health Inc. faced significant financial challenges in Q2 2025, reporting a 31.3% revenue drop and increased net losses. The company is adapting through strategic initiatives to enhance liquidity and operational efficiency as it navigates a turbulent healthcare landscape.

August 07, 2025 Evolent Health Inc. Reports Strong Q2 Performance Amidst Rising Demand for Specialty Care Solutions Evolent Health, Inc. reported mixed financial results for Q2 2025, with a revenue decline yet a positive adjusted EBITDA. The company focuses on expanding its specialty care services and partnerships, aiming to enhance profitability and health outcomes.

July 14, 2025 Evolent Health Inc. Prepares to Announce Q2 2025 Financial Results Evolent Health, Inc. will release its Q2 2025 financial results on August 7, 2025, with a conference call scheduled for 5 p.m. ET. The company aims to improve health outcomes for complex conditions and will also participate in upcoming investor events.

July 09, 2025 Evolent Health Inc. Announces Key Leadership Appointments to Propel Innovation in Specialty Care Evolent Health has appointed Dr. David Lim as Chief Clinical Officer and John Way as Chief Financial Officer, marking a strategic move to enhance specialty care. Their extensive expertise aims to drive innovation and improve health outcomes for patients with complex conditions.

June 20, 2025 Evolent Health Reiterates Q2 and Full-Year Guidance Amid Positive Oncology Trends Evolent Health has reiterated its Q2 and full-year 2025 guidance, buoyed by favorable oncology cost trends. The company also secured non-dilutive capital options to support its growth forecasts.

May 09, 2025 Evolent Health Inc. Reports 2025 Q1 Results: Navigating Challenges in a Changing Healthcare Landscape Evolent Health Inc. faced a challenging first quarter in 2025, reporting a 24.4% decline in revenue, attributed to rising medical claims costs and strategic transitions. Despite significant losses, the company is executing a repositioning plan aimed at enhancing value-based care solutions.

May 08, 2025 Evolent Health Inc. Reports First Quarter 2025 Results: A Mixed Bag Amid Strong Demand for Specialty Care Solutions Evolent Health's Q1 2025 results show a revenue decline of 24.4% and increased net losses, yet the company sees growth in memberships and new revenue agreements. CEO Seth Blackley emphasizes a strong selling environment and ongoing commitment to specialty care innovation.

April 22, 2025 Evolent Health Inc. Nominates Shawn Guertin for Board Election Evolent Health has nominated Shawn Guertin for election to its Board of Directors, highlighting his extensive experience in healthcare. If elected, he will replace long-serving member Diane Holder, marking a continued effort to enhance corporate governance.

April 15, 2025 Evolent Health Inc. Achieves Significant Reduction in Low-Value Oncology Regimens Evolent Health Inc. has successfully reduced low-value oncology regimens by over 20% through a comprehensive initiative aimed at improving cancer treatment quality. This program enhances patient outcomes while addressing the financial burdens associated with ineffective therapies.

April 10, 2025 Evolent Health Inc. Prepares for First Quarter 2025 Financial Results Release Evolent Health, Inc. will release its Q1 2025 financial results on May 8, 2025, followed by a conference call for detailed discussions. The company also highlights its participation in several upcoming investor conferences, reinforcing its commitment to stakeholder engagement.

February 21, 2025 Evolent Health Inc. Reports Annual Results for 2024: A Year of Transformation and Challenges Evolent Health's 2024 annual report reveals a 30.1% revenue increase to $2.55 billion, driven by its Performance Suite. Despite growth, the company faces challenges with rising operational costs and reported a net loss of $93.4 million.

February 20, 2025 Evolent Health Reports Strong Q4 and Full-Year 2024 Results Evolent Health, Inc. announced robust Q4 and full-year 2024 results, showcasing significant revenue and a perfect customer retention rate. The company is well-positioned for future growth despite challenges in the healthcare landscape.

February 07, 2025 SWOT Analysis of Evolent Health Inc. in 2025 This SWOT analysis of Evolent Health Inc. in 2025 outlines its strengths in innovative healthcare solutions and strategic partnerships, while acknowledging weaknesses like revenue dependency. The report highlights growth opportunities amid competitive and regulatory threats, crucial for the company's future success.

November 08, 2024 Evolent Health Inc. Reports Q3 2024 Financial Results: Revenue Growth Amid Cost Pressures Evolent Health Inc. reported a 21.6% revenue increase in Q3 2024, reaching $621.4 million, driven by its Performance Suite. Despite this growth, the company faced rising costs and reported a net loss of $31.23 million. Strategic acquisitions and investments in technology position Evolent for future opportunities in the evolving healthcare landscape.

August 09, 2024 Evolent Health Inc. Reports Strong Q2 2024 Results Amid Strategic Acquisition Evolent Health Inc. showcased impressive Q2 2024 results with a 37.9% revenue increase. Despite challenges, the company is well-positioned for growth following its acquisition of Machinify.

May 10, 2024 Evolent Health Inc. Reports Robust Growth in Q1 2024 Financial Results Evolent Health Inc. achieved a remarkable 49.6% revenue growth in Q1 2024, totaling $639.7 million, despite operational challenges. The company is optimistic about future growth following its strategic acquisitions and service expansions, even as it reported a net loss of $25.22 million.

Evolent Health Inc. Set to Release Q3 2025 Financial Results

Last updated: October 09, 2025 •

Taurigo

1. Scheduled Release and Conference Call

Evolent Health, Inc. (NYSE: EVH), a prominent player in the healthcare sector dedicated to improving health outcomes for individuals with complex health conditions, has announced the impending release of its third quarter 2025 financial results. The results are set to be unveiled on Thursday, November 6, 2025, after the market closes. Following the release, the company will conduct a conference call at 5 p.m. ET to discuss the results and provide insights into its operational performance.

2. Participation and Access

Shareholders and interested parties can listen to a live broadcast of the conference call through Evolent's investor relations website. The availability of an audio playback ensures that those unable to attend the live session can catch up on the discussion for up to 90 days after the event.

For analysts wishing to engage during the call, they can dial 855.940.9467 for domestic calls or 412.317.6034 for international inquiries. Participants are encouraged to call in 15 minutes prior to the start of the event and reference the "Evolent call."

3. Upcoming Investor Events

In addition to the earnings call, Evolent Health has lined up several key investor conferences that will feature presentations by its executive management team:

UBS Global Healthcare Conference: November 11, 2025, at the PGA National Resort in Palm Beach Gardens, Florida.

Stephens Investment Conference: November 18, 2025, at the Grand Hyatt in Nashville, Tennessee.

Piper Sandler 37th Annual Healthcare Conference: December 2-4, 2025, in New York, New York.

The company plans to provide live audio-only webcasts and replays for these events, which will be accessible in the "Events and Presentations" section of its investor relations website.

4. About Evolent Health

Evolent Health specializes in enhancing health outcomes for individuals with complex medical conditions through innovative solutions that aim to simplify and reduce the costs of healthcare. The company boasts a national client base comprising leading payers and providers, and it consistently earns recognition as a top employer in the healthcare industry.

Investors and stakeholders interested in Evolent's ongoing initiatives and performance are encouraged to visit their investor relations website for more detailed information.

As the healthcare landscape continues to evolve, Evolent Health remains at the forefront, dedicated to changing the way healthcare is delivered and ensuring better health outcomes for those in need.

Original press release

You may also be interested in: